Skip to content

Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors

A Prospective Feasibility Study Evaluating the Implementation of the Anticancer Lifestyle Program in Endometrial Cancer Survivors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06550791
Enrollment
23
Registered
2024-08-13
Start date
2024-09-04
Completion date
2025-09-28
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm, Uterine

Keywords

Endometrial Cancer, Holistic Cancer Treatment, Lifestyle Change

Brief summary

The purpose of this study is to promote positive lifestyle change among endometrial cancer survivors by using a group-based intervention. Endometrial cancer survivors are at an increased risk of other health conditions like heart disease, diabetes, and other cancers. The study team at the University of Virginia wants to explore new ways to lower these risks. This study will be evaluating the Anticancer Lifestyle program, which takes a more holistic approach and uses web-based learning modules along with weekly group sessions to discuss each topic of the web-based learning modules.

Interventions

BEHAVIORALAnticancer Learning Circle

All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* History of stage I-IV endometrial cancer, any histologic subtype * Completed cancer treatment, and in surveillance * Have no evidence of endometrial cancer as determined by primary oncologist * Be at least 18 years of age * Be able to read and communicate in English * Have a smartphone with access to cellular service or computer access with internet service * Must have technological competency/proficiency to use their Smartphone and/or computer, as self-reported by potential subject * Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion criteria

* Pregnant women * Prisoners * Subject is blind

Design outcomes

Primary

MeasureTime frameDescription
Number of participants that complete the programWeek 7The proportion of participants completing the program as defined by the number of those who participated in at least 75% of online sessions.

Secondary

MeasureTime frameDescription
Change from Week 0 of Generalized Anxiety Disorder (GAD-7) Survey from Baseline at Week 3232 weeksThe GAD-7 is a validated, self-reported survey assessing feelings of anxiety. Possible scores range from 0 (minimal anxiety) to 21 (severe anxiety). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 Score - Week 0 score)
Change from Week 0 of the Godin Leisure-Time Exercise Questionnaire (GLTEQ) from Baseline at Week 3232 weeksThe GLTEQ is a validated, self-reported scale assessing physical activity. Participants self-report the number of times per week they engage in strenuous, moderate, and mild/light physical activity. The self-reported number is multiplied by 9 for strenuous exercise, 5 for moderate exercise, and 3 for mild/light exercise. Scores can range from less than 14 units (insufficiently Active/Sedentary) to 24 units of more (Active). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)
Change from Week 0 of the Automated Self-administered 24-hour Dietary Assessment (ASA24) at Week 77 weeksThe Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool is a free, web-based tool created by the National Cancer Institute to assess nutritional intake. ASA24 enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries. Overall nutrition will be assessed at week 0 and week 7 to compare and evaluate changes in dietary patterns of participants.
Change from Week 0 of the Patient Health Questionnaire (PHQ-9) to Week 32Baseline and Week 32The PHQ-9 is a validated, self-reported scale to assess symptoms of major depressive disorder. Scores can range from 0 (none-Minimal) to 27 (severe). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)
Assess Attitudes Toward Group-Based Lifestyle Therapy Program Utilizing Internal Scale at Week 7 and Week 32Week 7 and Week 32Internal survey built to evaluate participants' satisfaction with the Anticancer Lifestyle Foundation's lifestyle program. Quantitative measures are gathered utilizing a scale of Strongly Disagree to Strongly Agree to assess participant attitudes towards program satisfaction, usefulness of information learned, and to gauge if the participant feels they were able to make positive lifestyle changes through participation in the program. Additional questions assess feelings towards preferences of group size, platform used, number of sessions, and length of program. Qualitive measure allows participants to share any thoughts/concerns/or feedback regarding the program.
Change from Week 0 of the Cancer Worry Scale (CWS) to Week 3232 weeksThe CWS scale is a validated, self-reported scale assessing participants worries about developing or reoccurring cancer. Scores can range from 8 (seldom or never worried) to 32 (worried a lot/almost all the time). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026